Page last updated: 2024-12-05
dihydrosafrole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 7197 |
| CHEBI ID | 82319 |
| SCHEMBL ID | 429483 |
| MeSH ID | M0108494 |
Synonyms (50)
| Synonym |
|---|
| benzene, 1,2-(methylenedioxy)-4-propyl- |
| 1,3-benzodioxole, 5-propyl- |
| nsc27867 |
| 94-58-6 |
| [1,2-(methylenedioxy)-4-propyl]benzene |
| wln: t56 bo do chj g3 |
| 2',3'-dihydrosafrole |
| 4-propyl-1,2-(methylenedioxy)benzene |
| 1, 5-propyl- |
| dihydroisosafrole |
| dihydrosafrol |
| benzene,2-(methylenedioxy)-4-propyl- |
| dihydrosafrole |
| 5-propyl-1,3-benzodioxole |
| safrole, dihydro- |
| nsc-33707 |
| nsc-27867 |
| nsc33707 |
| 1,2-(methylenedioxy)-4-propylbenzene |
| nsc 27867 |
| ccris 244 |
| ai3-03435 |
| rcra waste number u090 |
| benzene, 1,2-methylenedioxy-4-propyl- |
| hsdb 2939 |
| brn 0131188 |
| 4-propyl-1,2-methylenedioxybenzene |
| einecs 202-344-9 |
| 1-(3,4-methylenedioxyphenyl)propane |
| rcra waste no. u090 |
| AKOS000276810 |
| C19229 |
| ec 202-344-9 |
| 5-19-01-00473 (beilstein handbook reference) |
| unii-2ml63plh7g |
| 2ml63plh7g , |
| 1,2-(methylenedioxy)-4-propylbenzene [hsdb] |
| dihydrosafrole [iarc] |
| dihydrosafrole (prohibited) [fhfi] |
| SCHEMBL429483 |
| CHEBI:82319 |
| 2-(3,4-methylenedioxyphenyl)ethyl methane |
| 3,4-methylenedioxy phenylpropane |
| W-100191 |
| 5-propylbenzo[d][1,3]dioxole |
| DTXSID7020475 |
| 3,4-methylene-dioxyphenylpropane |
| dihydrosafrol 10 microg/ml in methanol |
| Q27155872 |
| 1,3-benzodioxole-5-propyl |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| benzodioxoles | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.42) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||